Sanofi nominates director to Regeneron Pharmaceuticals board
Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds
Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall
Global M&A By the Numbers: Q1 2022
Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes
Regeneron Pharmaceuticals Inc. added Tony Coles to its board.
The director was nominated by Sanofi, which owns 21.9% of the company, according to S&P Capital IQ data.
Coles is the chairman and CEO of Yumanity Therapeutics.